Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted oral protein degradation therapies. Dunad’s platform enables selective degradation via direct target modification using tunable mono-valent small molecules, allowing for the development of more drug-like, orally bioavailable and CNS-accessible protein degraders.

Dunad Therapeutics

Pearl Huang

Jon Garen

Elayne Penebre

Kathryn McNaughton

Holly Whittemore

Ruben Tommasi

The Biology Team at Dunad Therapeutics conducts cutting-edge research to identify and validate therapeutic targets for next-generation oral protein degradation therapies. They are responsible for developing and optimizing biological assays, characterizing the molecular mechanisms of target degradation, and evaluating the efficacy and specificity of tunable mono-valent small molecules in preclinical models.

Biology Team

About

Team members

Other teams at Dunad Therapeutics

Leadership Team